Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders

TY - JOUR

T1 - Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders

AU - Sönmezer, Murat

AU - Özmen, B.

AU - Çil, A. P.

AU - Özkavukçu, S.

AU - Taşçi, T.

AU - Olmuş, H.

AU - Atabekoǧlu, C. S.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - The effect of dehydroepiandrosterone (DHEA) supplementation on cycle outcome was assessed in patients with poor ovarian response. In total, 19 poor responder patients who were scheduled to undergo a second intracytoplasmic sperm injection (ICSI)/embryo transfer cycle were enrolled and first ICSI/embryo transfer cycles were taken as the control group. All subjects were given DHEA supplementation (25 mg t.i.d.) for at least 3 months prior to their second ICSI/embryo transfer cycle. In both cycles a fixed dose of rFSH (300 IU/day) and human menopausal gonadotrophin (HMG) (75 or 150 IU/day) along with a flexible gonadotrophin-releasing hormone (GnRH) antagonist protocol were administered. A favourable decrease was noted in mean day 3 serum oestradiol concentrations after DHEA supplementation (75.14 ± 28.93 versus 43.07 ± 11.77; P < 0.01). Increased number of >17 mm follicles (3 ± 0.7 versus 1.9 ± 1.3; P < 0.05), MII oocytes (4 ± 1.8 versus 2.1 ± 1.8; P < 0.05), top quality day 2 (2.2 ± 0.8 versus 1.3 ± 1.1; P < 0.05) and day 3 embryos (1.9 ± 0.8 versus 0.7 ± 0.6; P < 0.05) were achieved in DHEA-supplemented cycles. Cycle cancellation rates were reduced (5.3% versus 42.1%; P < 0.01), and the pregnancy rate per patient and clinical pregnancy rate per embryo transfer (47.4% versus 10.5%; P < 0.01 and 44.4% versus 0%; P < 0.01) were improved after DHEA supplementation. DHEA supplementation might enhance ovarian response, reduce cycle cancellation rates and increase embryo quality in poor responders.

AB - The effect of dehydroepiandrosterone (DHEA) supplementation on cycle outcome was assessed in patients with poor ovarian response. In total, 19 poor responder patients who were scheduled to undergo a second intracytoplasmic sperm injection (ICSI)/embryo transfer cycle were enrolled and first ICSI/embryo transfer cycles were taken as the control group. All subjects were given DHEA supplementation (25 mg t.i.d.) for at least 3 months prior to their second ICSI/embryo transfer cycle. In both cycles a fixed dose of rFSH (300 IU/day) and human menopausal gonadotrophin (HMG) (75 or 150 IU/day) along with a flexible gonadotrophin-releasing hormone (GnRH) antagonist protocol were administered. A favourable decrease was noted in mean day 3 serum oestradiol concentrations after DHEA supplementation (75.14 ± 28.93 versus 43.07 ± 11.77; P < 0.01). Increased number of >17 mm follicles (3 ± 0.7 versus 1.9 ± 1.3; P < 0.05), MII oocytes (4 ± 1.8 versus 2.1 ± 1.8; P < 0.05), top quality day 2 (2.2 ± 0.8 versus 1.3 ± 1.1; P < 0.05) and day 3 embryos (1.9 ± 0.8 versus 0.7 ± 0.6; P < 0.05) were achieved in DHEA-supplemented cycles. Cycle cancellation rates were reduced (5.3% versus 42.1%; P < 0.01), and the pregnancy rate per patient and clinical pregnancy rate per embryo transfer (47.4% versus 10.5%; P < 0.01 and 44.4% versus 0%; P < 0.01) were improved after DHEA supplementation. DHEA supplementation might enhance ovarian response, reduce cycle cancellation rates and increase embryo quality in poor responders.

KW - DHEA supplementation

KW - GnRH antagonist

KW - ICSI

KW - Poor ovarian response

UR - https://www.scopus.com/pages/publications/70449127166

U2 - 10.1016/j.rbmo.2009.06.006

DO - 10.1016/j.rbmo.2009.06.006

M3 - Article

C2 - 19909591

AN - SCOPUS:70449127166

SN - 1472-6483

VL - 19

SP - 508

EP - 513

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

IS - 4

ER -